Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Ibrutinib (PCI-32765) is a highly potent oral Bruton tyrosine kinase (BTK) inhibitor in clinical development for treating B-cell lymphoproliferative diseases. Patients with chronic lymphocytic leukemia (CLL) often show marked, transient increases of circulating CLL cells following ibrutinib treatmen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F. M., Magadala, Padmaja, Steggerda, Susanne M., Huang, Min Mei, Kuil, Annemieke, Herman, Sarah E. M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., Elias, Laurence
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3790509/
https://ncbi.nlm.nih.gov/pubmed/23940282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-482125
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados